506 Carnegie Center Drive, Suite 400
138 articles with Sandoz
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
Sandoz launches authorized generic of Narcan® (naloxone hydrochloride) Nasal Spray 4 mg in US to help reverse opioid overdose, expanding access during surge in overdose deaths
Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of its authorized generic of Narcan® (naloxone hydrochloride)* Nasal Spray 4mg, which is used to reverse opioid overdose.
Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.
After indicating it might entertain a sale, Novartis may receive an offer from investment group EQT and the Struengmann family for its generic unit Sandoz.
Novartis is the subject of a DOJ inquiry over the company’s marketing and pricing of Entresto over the past five years, receiving a Civil Investigative Demand from the government.
Novartis is reviewing its Sandoz division to determine the best moves to maximize value for shareholders. The strategic review will explore all options for the Swiss pharma giant.
Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)
Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin ® (Bevacizumab)
Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia
- Patients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable price
Sandoz announces generic Treprostinil Injection now also available for subcutaneous route of administration to treat PAH patients in US
- Treprostinil is indicated for Pulmonary Arterial Hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise¹ - PAH is rare, progressive disease with no cure that primarily affects women, often in their 30s to 60s, and may result in heart failure and shortened life expectancy² - Sandoz generic Treprostinil Injection now available for both subcutaneous and intravenous administration, providing PAH patients two options at lower cost
The high court’s decision will prevent Sandoz from launching its biosimilar to Amgen’s blockbuster rheumatoid arthritis drug.
ANI Pharmaceuticals, Inc. announced that it has acquired the new drug applications for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals.
Sandoz in-licenses brand and authorized generic of respiratory medicine Proventil® HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, with immediate generic availability in US
Sandoz Inc. today announced the in-licensing of commercial distribution rights to the brand and authorized generic of respiratory inhalation medicine Proventil® HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, a global contract development and manufacturing organization supplying the product.
Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals
Sandoz Inc. today announced it has entered into a long-term agreement with Civica Rx (Civica, Inc.) to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient car
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
The U.S. Department of Justice charged New Jersey-based Sandoz with four counts of conspiring to rig bids and fix prices for generic drugs.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
Adamas grants Sandoz license for its generic version of GOCOVRI® as of March 4, 2030 – over 12 years post GOCOVRI launch
Ziextenzo (pegfilgrastim) is a long-acting version of filgrastim and is indicated to decrease the incidence of infection in cancer patients.
NDMA is classified as a probable human carcinogen